Back to Search
PAULA MAPLES, PHARM.D.
PHARM.D.
Pharmacist
NPI: 1700071842Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
PHI-011835(GA)
Research & Publications (16)
Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.
PMID 19287371·Cancer Gene Ther·2009
3-trial
Systemic therapeutic gene delivery for cancer: crafting Paris' arrow.
PMID 19275571·Curr Gene Ther·2009
6-review
Emergency use regulatory approval process for experimental gene-based therapy.
PMID 18936466·J Clin Oncol·2008
8-other
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
PMID 18802154·J Clin Oncol·2008
3-trial
Stathmin 1: a novel therapeutic target for anticancer activity.
PMID 18759697·Expert Rev Anticancer Ther·2008
6-review
Compassionate approval process for experimental gene-based products.
PMID 18398156·J Clin Oncol·2008
5-case
A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients.
PMID 17704755·Cancer Gene Ther·2007
3-trial
Proof concept for clinical justification of network mapping for personalized cancer therapeutics.
PMID 17541424·Cancer Gene Ther·2007
8-other
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
PMID 16966690·J Clin Oncol·2006
3-trial
Effect of methylprednisolone on return of sexual function after nerve-sparing radical retropubic prostatectomy.
PMID 15533491·Urology·2004
3-trial
Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.
PMID 14970281·J Natl Cancer Inst·2004
3-trial
Potential clinical application of antioncogene ribozymes for human lung cancer.
PMID 14700482·Clin Lung Cancer·2001
8-other
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.
PMID 11420638·Gene Ther·2001
3-trial
Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.
PMID 11103798·Cancer Res·2000
3-trial
Cellular immune profile of patients with advanced cancer before and after taxane treatment.
PMID 11039505·Am J Clin Oncol·2000
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 50 IRVING ST NW
WASHINGTON, DC 20422 - Phone
- (202) 745-8000
Quick Facts
- NPI
- 1700071842
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 16
Are you this provider?
Claim Your Profile